|17th February 2021||Alexandria Forbes||15,000||Open or private sale||$15.57||$233,550.00|
|16th February 2021||Alexandria Forbes||15,000||Open or private sale||$15.60||$234,000.00|
|15th February 2021||Nicole Seligman||5,718||Exercise of derivative||$0.00|
|15th February 2021||Nicole Seligman||104||Grant/award etc.||$0.00|
|8th February 2021||Advisors Llc Perceptive||1,250,000||Open or private purchase||$16.00||$20,000,000.00|
|8th February 2021||Advisors Llc Perceptive||1,770,600||Conversion of derivative||$0.00|
|8th February 2021||Advisors Llc Perceptive||2,941,769||Conversion of derivative||$0.00|
|8th February 2021||Advisors Llc Perceptive||2,857,795||Conversion of derivative||$0.00|
|28th January 2021||Advisors Llc Perceptive||4,219,409||Open or private purchase||$2.37||$9,999,999.33|
|25th January 2021||Advisors Llc Perceptive||311,111||Open or private purchase||$22.50||$6,999,997.50|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
MeiraGTx Holdings Plc is a clinical-stage biotech company. It engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.